Showing results (591-600 of 692) with videos related to
Sort By:
Pageof 70
ACS Combinatorial Science|December 15, 2015
Direct Phenotypic Screening in Mice: Identification of Individual, Novel Antinociceptive Compounds from a Library of 734,821 Pyrrolidine Bis-piperazinesRichard A Houghten, Michelle L Ganno, Jay P McLaughlin, et al.Allergy and Asthma Proceedings|December 10, 2016
A comparison of seasonal trends in asthma exacerbations among children from geographic regions with different climatesJulia A Wisniewski, Anne P McLaughlin, Philip J Stenger, et al.The Science of the Total Environment|May 31, 2001
Integrated natural radiation exposure studies in stable Yugoslav rural communitiesZ S Zunic, J P McLaughlin, C Walsh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2009
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphomaB Esmaeli, P McLaughlin, B Pro, et al.Journal of Helminthology|January 6, 2012
Digenean metacercariae of fishes from the lagoon flats of Palmyra Atoll, Eastern Indo-PacificV M Vidal-Martínez, M L Aguirre-Macedo, J P McLaughlin, et al.The AAPS Journal|July 22, 2020
Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In VivoSebastiano Intagliata, Abhisheak Sharma, Tamara I King, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC seriesA López-Guillermo, F Cabanillas, P McLaughlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapyM F da Cunha, M L Meistrich, L M Fuller, et al.British Journal of Haematology|February 1, 1997
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trialA Younes, J P Ayoub, A Sarris, et al.Head & Neck|May 1, 1995
Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neckM P McLaughlin, W M Mendenhall, A A Mancuso, et al.Pageof 70